First Fertility Bishkek
First Fertility Bishkek
Scoring Methodology
Each dimension 1–5, based on public signals; first-party claims are excluded from objective scoring.
- Compliance
- 2.5
- Medical level
- —
- Transparency
- 2.0
- Reputation
- 2.0
- Intl. accessibility
- 4.0
See the Methodology.
Strengths
- NASDAQ-listed parent means SEC filings are publicly checkable — rare for this market
- WeChat support (ffgclinic) and Singapore hotline; clearly serves Chinese clients
Concerns
- Parent did four reverse splits in 2025 (cumulative approx. 1:2000) to hold the $1 bid price; going-concern/funding risk for long surrogacy timelines
- No doctors named for Bishkek ("to be updated"), no prices, Gmail contact address
- SEC filing frames Kyrgyzstan as a low-cost surrogate-supply jurisdiction; Bishkek is a surrogacy delivery site, not a full IVF center
Controversies & risks
- Parent NewGenIvf's post-IPO stock collapse and repeated reverse splits; Nasdaq hearings panel granted conditional continued listing in Feb 2025 (financial, not medical, controversy)
Score context: vs. peers in this country
Each dimension compared with the average of clinics we cover in the same country; “verified data points” are the public signals behind the score.
Ranked #4 by overall score among the 12 Kyrgyzstan providers we cover.
- Accreditations listed: Per parent's SEC prospectus: Bishkek clinic established Oct 2019, licensed 2020 (license number not disclosed)
- 1 controversy record(s)
- Founded: 2019
- Specialties: IVF, ICSI, Gender selection (group technology), Surrogacy
- Pricing disclosed
- Success rate self-reported, not third-party verified
- Third-party rating: WhatClinic ServiceScore 6.1/10 (3 votes, Jul 2026)
- Accepts Chinese clients: Yes
- Chinese-language service: Yes
Scores are editorial and conservative; dimensions with thin data are left unscored.
First Fertility Bishkek (est. October 2019, licensed 2020 per SEC filings) is the Kyrgyz surrogacy arm of NASDAQ-listed NewGenIvf (NIVF), whose main clinics are in Bangkok and Phnom Penh. It markets IVF/ICSI, gender selection and surrogacy with WeChat support aimed at Chinese clients, but names no doctors, publishes no prices, and its parent needed four reverse stock splits in 2025 to stay listed — a material counterparty risk for multi-year surrogacy contracts. Marked "caution".
The full researched review — sources, SEC findings and scoring rationale — is available on the Chinese version of this page (/clinics/kg-first-fertility).
Pre-contract due-diligence checklist
The top half is what we have verified from public signals; the bottom half is what you should verify yourself.
Verified by us (as of last-verified date)
- International accreditation · Verified
Per parent's SEC prospectus: Bishkek clinic established Oct 2019, licensed 2020 (license number not disclosed) - Price transparency · Verified
Not published (Jul 2026) - Success-rate claims · Caution
Self-reported: Group claims 82.5% success rate in 2024 (self-reported, methodology unstated) - Third-party reputation · Verified
WhatClinic ServiceScore 6.1/10 (3 votes, Jul 2026) - Controversy records · Caution
1 record(s) — see “Controversies” above - Current availability · Caution
Parent NewGenIvf (NASDAQ: NIVF) executed four reverse stock splits in 2025 to keep its listing; market cap approx. $7.6M in June 2026
Verify yourself
- Have the contract reviewed by an independent lawyer (not one referred by the provider)
- Ask for live-birth rates by age bracket, not a headline “success rate”
- Request an itemised fee schedule; confirm currency and refund terms
- Confirm ownership, transfer and disposal terms for medical records and embryos
- If possible, visit the clinic, lab and ward in person before signing
Reviews
To be verified
Frequently asked questions
Answers are based solely on information we have verified, with a last-verified date; not medical or legal advice.
Q1.Does First Fertility Bishkek accept Chinese clients?
Per public information, yes. Chinese-language service is offered. (last verified 2026-07-02)
Q2.How much does First Fertility Bishkek cost?
Publicly listed range: Not published (Jul 2026). Request an itemised written quote before signing. (last verified 2026-07-02)
Q3.Are First Fertility Bishkek's success-rate claims reliable?
The provider self-reports “Group claims 82.5% success rate in 2024 (self-reported, methodology unstated)”. This is unverified; ask for live-birth rates by age bracket instead. (last verified 2026-07-02)
Q4.What accreditations does First Fertility Bishkek hold?
Listed: Per parent's SEC prospectus: Bishkek clinic established Oct 2019, licensed 2020 (license number not disclosed). Verify certificates directly before signing. (last verified 2026-07-02)
Q5.How does this site review First Fertility Bishkek?
Five independent 1–5 scores (compliance, medical quality, transparency, reputation, international accessibility) based only on public signals and third-party feedback; self-descriptions don't count toward objective items. We charge providers nothing. See the Methodology page.
Other providers in the same country
Same-country providers ordered by overall score, for side-by-side comparison.
Delta Fertility (Delta Clinic KG)
Bishkek
Tulip International Reproductive Center
Bishkek, 47 Kurmanjan Datka St
Ecomed Bishkek
Bishkek, Gogolya 133